ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CMRA Comera Life Sciences Holdings Inc

0.045
0.00 (0.00%)
Apr 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.0451
Ask Price 0.065
News -
Day High

Low
0.0416

52 Week Range

High
0.9417

Day Low
Company Name Stock Ticker Symbol Market Type
Comera Life Sciences Holdings Inc CMRA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.045 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.045 0.045
Trades Volume Avg Volume 52 Week Range
0 0 - 0.0416 - 0.9417
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.045 USD

Comera Life Sciences Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.23M 30.74M - 633k -18.38M -0.60 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Comera Life Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CMRA Message Board. Create One! See More Posts on CMRA Message Board See More Message Board Posts

Historical CMRA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.28260.37490.04160.2871738201,674-0.2376-84.08%
1 Year0.94170.94170.04160.3739993103,037-0.8967-95.22%
3 Years9.7511.440.04163.18984,269-9.71-99.54%
5 Years9.7511.440.04163.18984,269-9.71-99.54%

Comera Life Sciences Description

Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.

Your Recent History

Delayed Upgrade Clock